$CGEM News

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Taiho Oncology and Cullinan Therapeutics Say Data From Cohort C Of Phase 2 REZILIENT2 Trial Of Zipalertinib For Locally Advanced Or Metastatic Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Or Uncommon EGFR Mutations and Active CNS Metastases Shows Intracranial Objective Response Rate Of 30.2% In 43 Evaluable Patients

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data

Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed?

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call - Slideshow